Ipatasertib - Genentech

Drug Profile

Ipatasertib - Genentech

Alternative Names: GCD 0068; GDC-0068; RG-7440

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Array BioPharma
  • Developer Chugai Pharmaceutical; Genentech; Queen Mary University of London; Roche Farma; SOLTI Breast Cancer Research Group
  • Class Antineoplastics; Heterocyclic bicyclo compounds; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer; Prostate cancer
  • Phase II Gastrointestinal cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 28 Sep 2018 Phase-II clinical trials in Breast cancer (Combination therapy, In adults, In the elderly) in United Kingdom (PO) (EudraCT2018-000977-62)
  • 24 Sep 2018 Ipatasertib is still in phase I trials for Solid tumours (Combination therapy, Late-stage disease) in United Kingdom
  • 13 Aug 2018 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease) in United Kingdom (PO) (NCT03673787)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top